Volume 25, No 8, Aug 2015
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 25 Issue 8, August 2015: 985-988
LETTERS TO THE EDITOR
Opposing roles of conventional and novel PKC isoforms in Hippo-YAP pathway regulation
Rui Gong1,2,3, Audrey W Hong1, Steven W Plouffe1, Bin Zhao4, Guangbo Liu1, Fa-Xing Yu5, Yanhui Xu1,2,3 and Kun-Liang Guan1
1Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA
2Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
3Institute of Biomedical Sciences, Shanghai Medical College of Fudan University, Shanghai 200032, China
4Life Sciences Institute and Innovation Center for Cell Biology, Zhejiang University, Hangzhou, Zhejiang 310058, China
5Children's Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China
Correspondence: Fa-Xing Yu, E-mail: fxyu@fudan.edu.cn; Yanhui Xu, E-mail: xuyh@fudan.edu.cn; Kun-Liang Guan,(kuguan@ucsd.edu)
The Hippo-YAP pathway is an evolutionally conserved signaling module that controls tissue growth during development and its dysregulation causes cancer1. Core components of the Hippo pathway include a kinase cascade comprising MST1/2 and LATS1/2 kinases, in which MST1/2 phosphorylates and activates...
10.1038/cr.2015.88
FULL TEXT | PDF
Browse 2184
